JAN 2 1 7075 ES

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 2

a collection of information unless it displays	a valid OMB control number.
Application Number	10/656,934
Filing Date	September 5, 2003
First Named Inventor	Battista et al.
Group Art Unit	1625
Examiner Name	Rita J. Desai
Attorney Docket Number	PRD0039USNP
-	

U.S. PATENT DOCUMENTS U.S. Patent Document Date of Publication Pages, Columns, Lines, Name of Patentee or Applicant of Cited Document where relevant passages or relevant figures appear Cite Examiner of Cited Document (if known) Number mm-dd-yyyy No. Hoffmann-La Roche Inc. 9-05-2000 6,113,527 Α

Examiner Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant	
		Office ³	Number ⁴	GindCode ⁵	Applicant of Cited Document	mm-dd-yyyy	passages or relevant figures appear	70
B		wo	01/96337	A1	Banyu Pharmaceutical Co., Ltd.	6-08-2001		Ŀ
R		wo	03/010168	A1	Banyu Pharmaceutical Co., Ltd.	7-23-2001		
CP		wo	02/085355	A1	Euro-Cettique, S.A.	10-31-2002		_
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	i –	<u> </u>		-				
						1000		<u> </u>

Signature | Date Considered | T/25/05 |
"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number, 2 See attached Kinds of U.S. Patent Documents, 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

PTQ/\$B/08A (08-00) Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 2

a consciou oi inominaton misse ii mahala	a valu Omb Comporticitudes.
Application Number	10/656,934
Filing Date	September 5, 2003
First Named Inventor	Battista et al.
Group Art Unit	1625
Examiner Name	Rita J. Desai
Attorney Docket Number	PRD0039USNP

	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), votume-Issue number(s), publisher, city and/or country where published Ronzoni, Silvano et al., "Lead generation and lead optimization approaches in the discovery of selective, non-peptide ORL-1 receptor agonists and antagonists," Exp. Optn. Ther. Patents, 2001, (11)4, pp. 525-546 Zaveri, Nurulain, "Peptide and nonpeptide tigands for the nociceptin/orphanin FQ receptor ORL1: Research tools and potential therapeutic agents," Life Sciences 73 (2003), pp. 663-678 Jenck, François et al., "A synthetic agonist at the orphanin FQ/nociceptin receptor ORL1: Anxiolytic profile in the ret," PNAS,	T²
80	receptor agonists and antagonists, "Exp. Opin. Ther. Patents, 2001, (11)4, pp. 525-646 Zaverl, Nurutain, "Peptide and nonpeptide tigands for the nociceptin/orphanin FQ receptor ORL1: Research tools and potential therapeutic agents," Life Sciences 73 (2003), pp. 663-678	
80/	potential therapeutic agents," Life Sciences 73 (2003), pp. 663-678	
	Jenck, François et at., "A synthetic agonist at the orphanin FQ/nociceptin receptor ORL1: AnxioNtic profile in the rat." PNAS.	
Ø.	April 25, 2000, vol. 97, no. 9, pp. 4938-4953	
B	Thomsen, Christan et al., "(8-Naphthalen-1-ylmethyl-4-oxo-1-phenyl-1,3,8-triaza-spiro[4.5]-dec-3-yl)-acetic acid methyl ester (NNC 63-0532) is a novel potent nociceptin receptor agonist," British Journal of Pharmacology (2000) 131, 903-908	

Examiner	KXIOAA	Date	7178	1 - 1
Signature	1 Delector	Considered	1/03	103

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number, 2 Applicant is to place a check mark here if English language Translation is attached.